Literature DB >> 11588100

Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion.

J C Wanstall1, T K Jeffery, A Gambino, F Lovren, C R Triggle.   

Abstract

1. Vasorelaxant properties of three nitric oxide (NO) donor drugs (glyceryl trinitrate, sodium nitroprusside and spermine NONOate) in mouse aorta (phenylephrine pre-contracted) were compared with those of endothelium-derived NO (generated with acetylcholine), NO free radical (NO*; NO gas solution) and nitroxyl ion (NO(-); from Angeli's salt). 2. The soluble guanylate cyclase inhibitor, ODQ (1H-(1,2,4-)oxadiazolo(4,3-a)-quinoxalin-1-one; 0.3, 1 and 10 microM), concentration-dependently inhibited responses to all agents. 10 microM ODQ abolished responses to acetylcholine and glyceryl trinitrate, almost abolished responses to sodium nitroprusside but produced parallel shifts (to a higher concentration range; no depression in maxima) in the concentration-response curves for NO gas solution, Angeli's salt and spermine NONOate. 3. The NO* scavengers, carboxy-PTIO, (2-(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide; 100 microM) and hydroxocobalamin (100 microM), both inhibited responses to NO gas solution and to the three NO donor drugs, but not Angeli's salt. Hydroxocobalamin, but not carboxy-PTIO, also inhibited responses to acetylcholine. 4. The NO(-) inhibitor, L-cysteine (3 mM), inhibited responses to Angeli's salt, acetylcholine and the three NO donor drugs, but not NO gas solution. 5. The data suggest that, in mouse aorta, responses to all three NO donors involve (i) activation of soluble guanylate cyclase, but to differing degrees and (ii) generation of both NO* and NO(-). Glyceryl trinitrate and sodium nitroprusside, which generate NO following tissue bioactivation, have profiles resembling the profile of endothelium-derived NO more than that of exogenous NO. Spermine NONOate, which generates NO spontaneously outside the tissue, was the drug that most closely resembled (but was not identical to) exogenous NO.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588100      PMCID: PMC1572971          DOI: 10.1038/sj.bjp.0704269

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation.

Authors:  C M Tseng; M A Tabrizi-Fard; H L Fung
Journal:  J Pharmacol Exp Ther       Date:  2000-02       Impact factor: 4.030

2.  Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide.

Authors:  P R Myers; R L Minor; R Guerra; J N Bates; D G Harrison
Journal:  Nature       Date:  1990-05-10       Impact factor: 49.962

Review 3.  Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system.

Authors:  S A Waldman; F Murad
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

4.  Nitric oxide and sodium nitroprusside-induced relaxation of the human umbilical artery.

Authors:  F Lovren; C Triggle
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

5.  Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta.

Authors:  A Ellis; C G Li; M J Rand
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

6.  Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor.

Authors:  K L Homer; J C Wanstall
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

7.  L-cysteine augments the vasorelaxation induced by sodium nitrite and SIN-1 but not that due to acetylcholine.

Authors:  P Arvola; I Pörsti; P Vuorinen; H Huhtala; T Metsä-Ketelä; H Vapaatalo
Journal:  Eur J Pharmacol       Date:  1992-04-22       Impact factor: 4.432

8.  Interaction of glyceryl trinitrate and sodium nitroprusside with bovine pulmonary vein homogenate and 10,000 x g supernatant: biotransformation and nitric oxide formation.

Authors:  G S Marks; B E McLaughlin; L B Brown; D E Beaton; B P Booth; K Nakatsu; J F Brien
Journal:  Can J Physiol Pharmacol       Date:  1991-06       Impact factor: 2.273

9.  Differential effects of hydroxocobalamin on NO-mediated relaxations in rat aorta and anococcygeus muscle.

Authors:  M A Rajanayagam; C G Li; M J Rand
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

10.  Differential effects of hydroxocobalamin on relaxations induced by nitrosothiols in rat aorta and anococcygeus muscle.

Authors:  M J Rand; C G Li
Journal:  Eur J Pharmacol       Date:  1993-09-14       Impact factor: 4.432

View more
  35 in total

Review 1.  NO and the vasculature: where does it come from and what does it do?

Authors:  Karen L Andrews; Chris R Triggle; Anthie Ellis
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

2.  A novel role for HNO in local and spreading vasodilatation in rat mesenteric resistance arteries.

Authors:  Kathryn H Yuill; Polina Yarova; Barbara K Kemp-Harper; Christopher J Garland; Kim A Dora
Journal:  Antioxid Redox Signal       Date:  2010-10-07       Impact factor: 8.401

Review 3.  The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO.

Authors:  Nazareno Paolocci; Matthew I Jackson; Brenda E Lopez; Katrina Miranda; Carlo G Tocchetti; David A Wink; Adrian J Hobbs; Jon M Fukuto
Journal:  Pharmacol Ther       Date:  2006-11-29       Impact factor: 12.310

4.  The shy Angeli and his elusive creature: the HNO route to vasodilation.

Authors:  Nazareno Paolocci; David A Wink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

5.  Soluble guanylate cyclase is required for systemic vasodilation but not positive inotropy induced by nitroxyl in the mouse.

Authors:  Guangshuo Zhu; Dieter Groneberg; Gautam Sikka; Daijiro Hori; Mark J Ranek; Taishi Nakamura; Eiki Takimoto; Nazareno Paolocci; Dan E Berkowitz; Andreas Friebe; David A Kass
Journal:  Hypertension       Date:  2014-12-01       Impact factor: 10.190

Review 6.  A recent history of nitroxyl chemistry, pharmacology and therapeutic potential.

Authors:  Jon M Fukuto
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

7.  S-nitrosocaptopril: in vitro characterization of pulmonary vascular effects in rats.

Authors:  Debbie Y Y Tsui; Agatha Gambino; Janet C Wanstall
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury.

Authors:  Wei-Ping Wu; Jing-Xia Hao; Ennio Ongini; Francesco Impagnatiello; Cristina Presotto; Zsuzsanna Wiesenfeld-Hallin; Xiao-Jun Xu
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

9.  Endothelial nitric oxide synthase gene G894T polymorphism and risk assessment for pregnancy-induced hypertension: evidence from 11 700 subjects.

Authors:  Qiong Ma; Jianmin Lv; Kuikui Huang; Huaqi Guo; Wenliang Yang; Wen Luo; Jie Qiu; Lan Yang
Journal:  Hypertens Res       Date:  2016-07-28       Impact factor: 3.872

10.  The effects of nitroxyl (HNO) on soluble guanylate cyclase activity: interactions at ferrous heme and cysteine thiols.

Authors:  Thomas W Miller; Melisa M Cherney; Andrea J Lee; Nestor E Francoleon; Patrick J Farmer; S Bruce King; Adrian J Hobbs; Katrina M Miranda; Judith N Burstyn; Jon M Fukuto
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.